Table 2.
Comorbidity and medication at baseline.
| Variable | Number of patients (%) | P-value * | |
|---|---|---|---|
| Sitagliptin (n = 77) | Control (n = 71) | ||
| Comorbidity | |||
| Retinopathy | 7 (9.1) | 0 (0.0) | 0.01 |
| Nephropathy | 25 (32.5) | 17 (23.9) | 0.28 |
| Neuropathy | 4 (5.2) | 4 (5.6) | 1.00 |
| CAD | 11 (14.3) | 9 (12.7) | 0.81 |
| Stroke | 7 (9.1) | 5 (7.0) | 0.77 |
| Hypertension | 46 (59.7) | 41 (57.7) | 0.87 |
| Dyslipidemia | 51 (66.2) | 47 (66.2) | 1.00 |
| Liver disease | 10 (13.0) | 6 (8.5) | 0.43 |
| Kidney disease | 17 (22.1) | 11 (15.5) | 0.40 |
| Other diseases | 28 (36.4) | 28 (39.4) | 0.74 |
| Medication | |||
| Antidiabetics | 53 (68.8) | 60 (84.5) | 0.03 |
| Sulfonylureas | 27 (35.1) | 37 (52.1) | 0.046 |
| Metformin | 36 (46.8) | 33 (46.5) | 1.00 |
| Pioglitazone | 20 (26.0) | 17 (23.9) | 0.85 |
| α-Glucosidases | 12 (15.6) | 20 (28.2) | 0.07 |
| Glinides | 1 (1.3) | 2 (2.8) | 0.61 |
| Othersa | 2 (2.6) | 1 (1.4) | 1.00 |
| Antihypertensives | 43 (55.8) | 35 (49.3) | 0.51 |
| Lipid-lowering drug | 43 (55.8) | 37 (52.1) | 0.74 |
| Other drugs | 34 (44.2) | 37 (52.1) | 0.41 |
*Between-group differences based on Fisher’s exact test. CAD coronary artery disease. aEpalrestat prescribed for diabetic neuropathy (n = 1 in sitagliptin group and n = 1 in control group) and imidapril for diabetic nephropathy (n = 1 in sitagliptin group) are listed as others (other antidiabetic medications).